Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Pacira BioSciences (PCRX) Non-Current Deferred Tax Liability (2025 - 2026)

Pacira BioSciences has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $4.1 million for Q1 2026.

For Q1 2026, Non-Current Deferred Tax Liability fell 41.5% year-over-year to $4.1 million; the TTM value through Mar 2026 reached $4.1 million, down 41.5%, while the annual FY2025 figure was $4.2 million, N/A changed from the prior year.
Non-Current Deferred Tax Liability for Q1 2026 was $4.1 million at Pacira BioSciences, down from $4.2 million in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $7.0 million in Q1 2025 and troughed at $4.1 million in Q1 2026.